Biohit Oyj

Declaration of Voting Results & Voting Rights Announcements • Mar 31, 2015

Disclosure 323139

Biohit Oyj - Total number of voting rights and capital

Biohit Oyj B-shares Subscribed with Stock Options II 2013

Biohit Oyj Stock Exchange Release March 31, 2015 at 9:30 a.m. local time (EET) A total number of 85,000 new Biohit Oyj B-shares have been subscribed for with stock options II 2013 during January 28th, 2015 and March 10th, 2015. These shares have been entered into the trade register on March 31st, 2015, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ OMX Helsinki as of April 1, 2015 together with the existing B-shares. The share subscription price was EUR 2.2766 per share respectively. The entire subscription price of EUR 193,511 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscription the number of all Biohit Oyj's shares will rise into 14,220,593 shares (14,135,593) and B-shares will rise into 11,245,093 shares (11,160,093). The new shares will correspond to a percentage of 0.6% of Biohit Oyj's total number of shares and 0.12% of the voting rights after registration. The share subscription period with stock options II 2013 began on July 1, 2013 and will end June 30, 2015. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 14, 2014. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is “Innovating for Health” - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com